Drug intelligence / Profile preview

VVD-101

Development stage: Phase 2
Lead developer: Vivid Pharma
Modality: Small Molecules
Administration: Oral

Overview

VVD-101 is an investigational fixed-dose oral capsule combining **sumatriptan succinate 12.5 mg** and **acetylsalicylic acid 325 mg**. It was developed by Vivid Pharma for acute treatment of delayed alcohol-induced headache. Sumatriptan is a serotonin 5-HT1B/1D receptor agonist, while aspirin inhibits cyclooxygenase enzymes to reduce prostaglandin-mediated pain and inflammation. A completed Phase 2 pilot trial evaluated VVD-101 against placebo in adults with delayed alcohol-induced headaches. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02176655))

Other names: aspirin + sumatriptanaspirin/sumatriptan

Targets

PGHS-1 (Prostaglandin G/H Synthase 1)HTR1B (5-Hydroxytryptamine Receptor 1B)HTR1D (5-hydroxytryptamine receptor 1D)

Beyond the preview

Go deeper on VVD-101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VVD-101.

Explore the full profile